EBAC
 
 
Powered by
EBAC on-line Accreditation Services Home | Discover EBAC on-line services | FAQ | Contact us
EBAC calendars
Events CDROMs
Web courses Articles to select a Calendar use this horizontal tabs
Search EBAC Web calendar
Keywords:
Additional search criteria:
Display archived modules (accreditation expires after 2 years)

Web calendar

Current selection criteria: No criteria
Click on a column name to sort the list
CME Provider Website title Module CME credits Expiry
Academic Medical Center Amsterdam. Dept Vascular Medicine
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc HbA1c in CVD 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc Hypoglycemia in CV medicine - why worry? 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc Key classes of antidiabetic drugs 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc Natural history of diabetes: focus on microvascular and macrovascular complications 1 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc T2DM and CV outcomes 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc Early intervention for lifetime CV risk reduction 1 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc Estimating CV risk and treatment benefit 0 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc Importance of hypertension in CVD prevention 0 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc The role of lipids in CVD prevention: Lessons learned about statins 0 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc Current management of heart failure & T2DM 1 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc Guidance from outcome trials: What are the clinical implications 0 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology 0 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Contemporary management of a patient with heart failure and diabetes: Implications from recent trials - https://pace-cmelearninglab.coursepath.com/1968642/course-toc Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes 0 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Diabetes, Cardiology & Novel Therapeutic Approaches - https://pace-cmelearninglab.coursepath.com/2755074/course-toc Diabetes & CVD: Time for a multifactorial approach 1 13 Mar 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Diabetes, Cardiology & Novel Therapeutic Approaches - https://pace-cmelearninglab.coursepath.com/2755074/course-toc Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control 0 13 Mar 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Diabetes, Cardiology & Novel Therapeutic Approaches - https://pace-cmelearninglab.coursepath.com/2755074/course-toc Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit? 0 13 Mar 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc Addressing the remaining questions on SGLT2 & CKD: A review of new outcome trials 0 07 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc SGLT2 inhibition in kidney disease: What are the key lessons from the EMPA-REG OUTCOME trial? 1 07 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition - https://pace-cmelearninglab.coursepath.com/2099714/course-toc Understanding CKD & SGLT2 inhibition: What are the key mechanisms for benefit? 0 07 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc Clinical trials in diabetes and CVD - What did we learn? 0 10 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc Novel diabetes drugs in clinical management: extending the opportunities 0 10 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc Translation of novel approaches in CVD & diabetes to clinical practice 0 10 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc What are the key mechanisms of CV benefit of novel diabetes drugs? 0 10 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Exploring the role of GLP-1 RA in the management of CVD & T2DM - https://pace-cmelearninglab.coursepath.com/1837570/course-toc What is the science driving CVD and T2DM? 1 10 Dec 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc Atrial fibrillation & HFpEF: Novel device and therapeutic approaches 0 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc Diabetes & Obesity in HFpEF: New targets in heart failure management 0 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction - https://pace-cmelearninglab.coursepath.com/1903106/course-toc HFpEF: from understanding the physiology to development of new treatments 1 19 Sep 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc Diabetes & CVD: Time for a multifactorial approach 1 17 Jan 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control 0 17 Jan 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice? - https://pace-cmelearninglab.coursepath.com/2624002/course-toc Translating GLP-1 trial outcomes to cardiology practice: Which patients will benefit? 0 17 Jan 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc Introduction 1 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY 0 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc PCSK9 as target for treatment: The genetic validation 0 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition: Science, outcomes & guidance - https://pace-cmelearninglab.coursepath.com/2558466/course-toc Targeting PCSK9 in clinical practice: Guidance & future 0 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc Guidelines and the role of non-statin therapies for high risk ASCVD patients 0 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc Identifying patients for PCSK9 therapy 1 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc Landmark trials with PCSK9 inhibitors 0 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9: Outcomes and trials in clinical perspective - https://pace-cmelearninglab.coursepath.com/2689538/course-toc PCSK9 inhibitors: How do they work? 0 22 Feb 2021
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc Diabetes: How to reduce risk from a cardiovascular perspective? 0 23 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc Practical management of cardiovascular risk: Lessons from latest diabetes trials 0 23 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Preventing cardiovascular disease in patients with T2DM - The role of GLP-1 RA - https://pace-cmelearninglab.coursepath.com/1772034/course-toc The cardiovascular challenge for primary care in diabetes 1 23 Aug 2020
AcademicCME
AcademicCME/ T. Hayes Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events - https://www.academiccme.com/ACS-Euro Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events 1 13 May 2022
Asian Pacific Society of Cardiology
Asian Pacific Society of Cardiology/ J. Tan GDF-15 and risk stratification in Atrial Fibrillation - https://event.on24.com/wcc/r/1773686/09ACB1305E44D118152C638A49141637 GDF-15 and new ABC-AF risk score in atrial fibrillation 1 16 Jul 2021
British Heart Rhythm Society
British Heart Rhythm Society/ J. Gill https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 Convergent ablation: The what and the why 0 27 Jun 2021
British Heart Rhythm Society/ J. Gill https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 The electrophysiologic problem leading to sub-optimal outcomes 0 27 Jun 2021
British Heart Rhythm Society/ J. Gill https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 The ongoing challenges of atrial fibrillation 1 27 Jun 2021
British Heart Rhythm Society/ J. Gill https://www.radcliffe-cme.com; Programme title: Convergent procedure: A new approach to atrial fibrillation ablation - https://www.radcliffe-cme.com/content/convergent-procedure-new-approach-atrial-fibrillation-ablation#group-tabs-node-course-default1 The role of the electrophysiologist in convergent ablation: The how and the who 0 27 Jun 2021
Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy
Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ Basic principles of 3D echocardiography 1 22 Jan 2022
Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ New anatomical and pathophysiological insights in tricuspid regurgitation 0 22 Jan 2022
Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ Quantitative assessment of the aortic valve 0 22 Jan 2022
Dept of Cardiac, thoracic and Vascular Science, University of Padua, Italy/ L. Badano How 3D Echocardiography has changed the way we look at valves using ultrasounds - http://3decho360.com/elearning/ Value of 3D Echo for the assessment of the Mitral Valve 0 22 Jan 2022
EXCEMED
EXCEMED/ S. Taddei Interactive clinical case: Heart failure - https://www.excemed.org/user/login?destination=excemedlearning/67 Interactive clinical case: Heart failure 1 20 Nov 2020
International Society of Cardiovascular Pharmacotherapy
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref ARIADNE in Review 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref Commentary on ARIADNE Trial 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref Commentary on PROVE-HF and EVALUATE-HF Trials 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref Commentary on the TRANSITION-CHF and PIONEER Trials 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref Conclusions 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref EVALUATE-HF in Review 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref PIONEER in Review 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref PROVE-HF in Review 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref TRANSITION-CHF in Review 0 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ A. Coats A Review of Emerging ARNI Data in HFrEF - https://www.radcliffeeducation.com/content/review-emerging-arni-data-hfref Welcome and Introduction 1 26 Nov 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 Current Guidelines, Recent Data, and Future Practices 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 DAPA-HF - Clinical Trial Design Rationale 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 DAPA-HF - Interview with the Trialist 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 SGLT2 in HF - Now and in the Future 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 SGLT2i Beyond Diabetes - Mechanism of Benefit in CVD 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 Summary and Conclusions 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 The Dapaglifozin and Prevention of Adverse Outcomes in HF Trial 0 29 Dec 2021
International Society of Cardiovascular Pharmacotherapy/ F. Martinez Current and Emerging Data on SGLT2 Inhibitors in Heart Failure - https://www.radcliffeeducation.com/content/current-and-emerging-data-sglt2-inhibitors-heart-failure#group-tabs-node-course-default1 Welcome and Introduction 1 29 Dec 2021
PACE-CME
PACE-CME/ J. Kastelein 4 Things a cardiologist should know about triglycerides - https://pace-cmelearninglab.coursepath.com/3344898/course-toc How can triglycerides increase CV risk? 0.17 21 Apr 2022
PACE-CME/ J. Kastelein 4 Things a cardiologist should know about triglycerides - https://pace-cmelearninglab.coursepath.com/3344898/course-toc Reducing triglycerides in REDUCE-IT 0.33 21 Apr 2022
PACE-CME/ J. Kastelein 4 Things a cardiologist should know about triglycerides - https://pace-cmelearninglab.coursepath.com/3344898/course-toc The spectrum of triglyceride-rich lipoproteins 0.33 21 Apr 2022
PACE-CME/ J. Kastelein 4 Things a cardiologist should know about triglycerides - https://pace-cmelearninglab.coursepath.com/3344898/course-toc Three lines of evidence for triglycerides as a CV risk factor 0.17 21 Apr 2022
PACE-CME/ J. Kastelein Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice - https://pace-cmelearninglab.coursepath.com/3148290/course-toc Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials 0 02 Jan 2022
PACE-CME/ J. Kastelein Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice - https://pace-cmelearninglab.coursepath.com/3148290/course-toc Importance of protection and prevention in cardiorenal disease 1 02 Jan 2022
PACE-CME/ J. Kastelein Impacting progression and outcomes of DKD: Translating novel insights with GLP-1RA to practice - https://pace-cmelearninglab.coursepath.com/3148290/course-toc The science behind vascular and renal benefits of GLP-1 receptor agonists 0 02 Jan 2022
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc Are very low LDL-c levels safe? 0 12 Jul 2021
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc Challenges for screening and treatment of FH patients in clinical cardiology 0 12 Jul 2021
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc Cholesterol guidelines in need of major changes? 0 12 Jul 2021
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc How are the guidelines for progressive CAD guiding us in clinical practice? 0 12 Jul 2021
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc LDL-c as target in cardiology: the road towards lower targets 1 12 Jul 2021
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc Progressive CAD despite low LDL-c, an elusive disease? 0 12 Jul 2021
PACE-CME/ J. Kastelein LDL-c lowering in high CV risk patients - https://pace-cmelearninglab.coursepath.com/2820610/course-toc What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol? 0 12 Jul 2021
PACE-CME/ J. Kastelein PCSK9i, changing practice in cardiology: The emerging story - https://pace-cmelearninglab.coursepath.com/3017218/course-toc Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients? 0 09 Dec 2021
PACE-CME/ J. Kastelein PCSK9i, changing practice in cardiology: The emerging story - https://pace-cmelearninglab.coursepath.com/3017218/course-toc Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most? 1 09 Dec 2021
PACE-CME/ J. Kastelein PCSK9i, changing practice in cardiology: The emerging story - https://pace-cmelearninglab.coursepath.com/3017218/course-toc Targeting PCSK9: Expanding knowledge and targeting new frontiers 0 09 Dec 2021
PACE-CME/ A. Voors RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes - https://pace-cmelearninglab.coursepath.com/2886146/course-toc Addressing the risk of hyperkalemia: is there a sweet spot for potassium binding? 0 23 Oct 2021
PACE-CME/ A. Voors RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes - https://pace-cmelearninglab.coursepath.com/2886146/course-toc Managing hyperkalemia in cardiorenal patients: Novel therapeutic insights to optimize outcomes 0 23 Oct 2021
PACE-CME/ A. Voors RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes - https://pace-cmelearninglab.coursepath.com/2886146/course-toc RAAS inhibition in patients with kidney disease: balancing the benefits and risks 1 23 Oct 2021
PACE-CME/ A. Voors Reshaping the future of heart failure management - Translating innovations to practice in HFpEF - https://pace-cmelearninglab.coursepath.com/2951682/course-toc Cardiac amyloidosis: An emerging target in HFpEF? 0 30 Jan 2022
PACE-CME/ A. Voors Reshaping the future of heart failure management - Translating innovations to practice in HFpEF - https://pace-cmelearninglab.coursepath.com/2951682/course-toc Heart failure & diabetes: What is the goal of treatment? 0 30 Jan 2022
PACE-CME/ A. Voors Reshaping the future of heart failure management - Translating innovations to practice in HFpEF - https://pace-cmelearninglab.coursepath.com/2951682/course-toc Understanding and managing obesity-related HFpEF 1 30 Jan 2022
PACE-CME/ A. Voors Reviewing HFpEF: Lessons and implications from PARAGON-HF - https://pace-cmelearninglab.coursepath.com/3410434/course-toc Heart failure with mid-range ejection fraction 0 02 May 2022
PACE-CME/ A. Voors Reviewing HFpEF: Lessons and implications from PARAGON-HF - https://pace-cmelearninglab.coursepath.com/3410434/course-toc HFpEF: a misunderstood disease in search of a therapy 0 02 May 2022
PACE-CME/ A. Voors Reviewing HFpEF: Lessons and implications from PARAGON-HF - https://pace-cmelearninglab.coursepath.com/3410434/course-toc PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF 1 02 May 2022
PACE-CME/ A. Voors SGLT2 inhibition in CKD: Discussing the key questions and evidence - https://pace-cmelearninglab.coursepath.com/3082754/course-toc Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes? 1 18 Dec 2021
PACE-CME/ A. Voors SGLT2 inhibition in CKD: Discussing the key questions and evidence - https://pace-cmelearninglab.coursepath.com/3082754/course-toc The clinical landscape of managing patients with CKD: Where are we now and what can we expect? 0 18 Dec 2021
PACE-CME/ A. Voors SGLT2 inhibition in CKD: Discussing the key questions and evidence - https://pace-cmelearninglab.coursepath.com/3082754/course-toc Underlying mechanisms of nephroprotective effects with SGLT2i in CKD 0 18 Dec 2021
University Medical Center Groningen
University Medical Center Groningen/ A. Voors HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc Current and future clinical approaches to manage HFpEF 0 22 Feb 2021
University Medical Center Groningen/ A. Voors HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc HFpEF: How to diagnose 0 22 Feb 2021
University Medical Center Groningen/ A. Voors HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc HFpEF: What are the most likely pathophysiological mechanisms involved in the disease 0 22 Feb 2021
University Medical Center Groningen/ A. Voors HFpEF: The essentials to know - https://pace-cmelearninglab.coursepath.com/2492930/course-toc HFpEF: What is it & size of the problem 1 22 Feb 2021
UpToDate
UpToDate/ T. Post UpToDate - https://www.uptodate.com UpToDate 1 29 Jan 2021

Privacy policy | Terms & conditions | Document library | Contact us     Copyright © 2008-2020 EBAC - All rights reserved